

Ref no: 257101220
From: Commercial
Date: 10/12/20
Subject: Usage of antiretroviral therapies

REQUEST & RESPONSE

I am analysing the usage of antiretroviral therapies. Could you please answer the following four questions?

Q1. How many patients were treated (for any condition) in the latest 6-month period with the following drugs:

- Juluca (rilpivirine/dolutegravir)
- Dovato (lamivudine/dolutegravir)
- Triumeq (abacavir/lamivudine/dolutegravir)
- Tivicay (dolutegravir)
- Isentress (raltegravir)
- Biktarvy (TAF/emtricitabine/bictegravir)
- Genvoya (TAF/emtricitabine/elvitegravir/cobisistat)
- Symtuza (TAF/emtricitabine/darunavir/cobisistat)
- Odefsey (TAF/emtricitabine/rilpivirine)
- Descovy (TAF/emtricitabine)
- Truvada or generic TDF/emtricitabine

BIKTARVY 50mg / 200mg / 25mg	27
DOLUTEGRAVIR	10
EMTRICITABINE 200mg / TENOFOVIR ALAFENAMIDE 25mg	*<5
GENVOYA	19
LAMIVUDINE	*<5
ODEFSEY 200mg / 25mg / 25mg	9
SYMTUZA 800 /150 /200 /10MG	21
TRIUMEQ 50mg/600mg/300mg	15
TRUVADA	27

Drugs not listed have not been dispensed.

Q2. How many patients received any antiretroviral (ART) therapy for HIV treatment (excluding pre-exposure prophylaxis):

- for the latest 6-month period
- for the 6 months from July-December 2019

ABACAVIR 600 mg / LAMIVUDINE 300 mg	*<5
ATRIPLA 600mg/200mg/245mg	6
BIKTARVY 50mg / 200mg / 25mg	27
DARUNAVIR	*<5
DARUNAVIR 800mg / COBICISTAT 150mg 'REZOLSTA'	*<5
DOLUTEGRAVIR	10
DORAVIRINE 100mg/ LAMIVUDINE 300mg/ TENOFVIR 245mg	*<5
EFAVIRENZ	*<5
EMTRICITABINE 200mg / TENOFVIR ALAFENAMIDE 25mg	*<5
EVIPLERA	9
GENVOYA	19
KIVEXA 600mg/300mg	*<5
LAMIVUDINE	*<5
MARAVIROC	*<5
NEVIRAPINE	*<5
ODEFSEY 200mg / 25mg / 25mg	9
RALTEGRAVIR	22
STRIBILD 150mg/150mg/200mg/245mg	*<5
SYMTUZA 800 /150 /200 /10MG	21
TENOFVIR	6
TRIUMEQ 50mg/600mg/300mg	15
TRUVADA	27

Q3. How many patients were treated in the latest 6-months period with Truvada or generic TDF/emtricitabine for:

- HIV treatment
- Pre-exposure prophylaxis (PrEP)

St Helens and Knowsley Teaching Hospitals NHS Trust does not hold this information. You may wish to re-direct your request to North West Boroughs Healthcare at the following:

<https://www.nwbh.nhs.uk/freedom-of-information>

Q4. How many packs of Truvada or generic TDF/emtricitabine were dispensed in latest 6-month period for:

- HIV treatment
- Pre-exposure prophylaxis (PrEP)

98 packs of truvada or generic TDF/emtricitabine were dispensed.

Regarding pre-exposure prophylaxis - St Helens and Knowsley Teaching Hospitals NHS Trust does not hold this information. You may wish to re-direct your request to North West Boroughs Healthcare at the following:

<https://www.nwbh.nhs.uk/freedom-of-information>

* **Please note:** We are unable to provide precise figures when those figures refer to individuals in volumes of 5 or less due to the risk that individuals will be re-identified, as we are required to protect their identity under the General Data Protection Regulations & Data Protection Act 2018. In such circumstances sections 40(2) and (3) of the Freedom of Information Act apply. In this case, our view is that disclosure would breach the first data protection principle. This states that personal data should be processed “lawfully, fairly and in a transparent manner”. It is the lawful aspect of this principle which, in our view, would be breached by disclosure. In such circumstances section 40 confers an absolute exemption on disclosure.